SpectronRx, a radiopharmaceutical developer and manufacturer, entered into a new partnership agreement with ARTBIO, Inc., a clinical-stage radiopharmaceutical company developing a new class of targeted alpha radioligand therapies (ART), to produce a novel prostate cancer therapy, AB001. SpectronRx will use its state-of-the-art facilities in Indiana to serve as a contract developer and manufacturer for the treatment currently undergoing first-in-human trials. The manufacturing processes will s...